In Vitro Susceptibility Data Provided Through the University of Pittsburgh Medical Center.
In Vitro Data Should Not Be Considered Representative of Clinical Efficacy1
Established therapeutic utility in blepharitis, conjunctivitis, and other superficial
ocular infections caused by Bacitracin-susceptible organisms
Excellent safety profile—low incidence of adverse events2
Ointment provides long-lasting ocular surface contact time and greater bioavailability3
Anti-infective efficacy in a lubricating base2
Flexible dosing—1 to 3 times daily2
Tier 1 pharmacy benefit status— on most insurance plans4
Indication
Bacitracin Ophthalmic Ointment is indicated for the treatment of superficial ocular infections involving the conjunctiva
and/or cornea caused by Bacitracin susceptible organisms.
Important Safety Information
This product should not be used in patients with a history of hypersensitivity to Bacitracin.
Bacitracin Ophthalmic Ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic.
There is a low incidence of allergenicity exhibited by Bacitracin. If such reactions do occur, therapy should be discontinued.
Click here for full prescribing information.
NDC |
Size |
Case Pack |
0574-4022-35 |
3.5 g |
144 / 12 |